Private Equity
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Investor profile
Private equityInvestments
64
17 of them startups
Hiring now
17
496 open roles
Exits
7
Focusshare of its companies
CRO & CDMO Services 13%Clinical Trial Services (CRO) 11%Drug Discovery 9%APIs & Drug Manufacturing 9%Laboratory Equipment 6%Genomics & Genetic Testing 5%Biologics & Biosimilars 5%Diagnostic Tests & IVD 5%
Where its companies are
United States 22%Germany 3%Ireland 2%Belgium 2%
Stage of its companies
Venture, series not stated 100%
Its companies, the freshest money firstAll 64 investments
Meadowhawk BiolabsVenture round $5M · 2 yr ago · 2 roles
SpecacVenture round · 2 yr ago
AnaBiosVenture round $6.5M · 4 yr ago
PerkinElmerVenture round $2.2B · 5 yr ago · 168 roles
Clario76 roles
Curia56 roles
Avid Bioservices44 roles
Recipharm18 roles
Genezen18 roles
MedPharm9 roles
Revvity5 roles
Vantage Medtech3 roles
Hiring fastestroles opened in 30 days
Co-investorscompanies they hold together
Similar investorstheir companies share markets and countries
Sources: its portfolio page, read Oct 3
Overview
Ampersand Capital Partners is a growth equity firm focused exclusively on healthcare and life sciences. It invests in companies providing pharmaceutical services, laboratory products, medical technology and healthcare services, often partnering with founders to build category leaders. The firm was established in 1988 as the successor to the venture capital group of PaineWebber and is headquartered in Wellesley, Massachusetts.
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Wellesley
United States
HQ
Boston
United States
Regional office
One Post Office Square, Suite 2900
Amsterdam
United States
Regional office
Ampersand Capital Partners

GHO Capital
ARCH Venture Partners
HBM Healthcare Investments
OrbiMed
Excel Venture Management
Xontogeny
EcoR1 Capital